Extended Data Table 3 Most frequent treatment-emergent adverse events related to pelabresib or placebo reported in at least 5% of patients in either arm

From: Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

  1. *Safety population includes all patients who received at least one dose of study drug.
  2. †‘Anemia’ includes preferred terms of anemia and hemoglobin decrease.
  3. ‡‘Thrombocytopenia’ includes preferred terms of thrombocytopenia and platelet count decrease.
  4. A treatment-emergent adverse event for the double-blinded treatment period is defined as an adverse event that has a start date on or after the first dose of pelabresib/placebo and before 30 days after the last dose of pelabresib/placebo or before the start of alternative (off-study) treatment for myelofibrosis, whichever occurs first. For any adverse event for which Common Terminology Criteria for Adverse Events grading does not exist, the Investigator assessed severity using the WHO grading system, where Grades 1–4 correspond to the severity of mild, moderate, severe, and life-threatening.
  5. WHO, World Health Organization.
Back to article page